The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Arcellx Gilead cancer therapy shows promise in multiple myeloma treatment trials
A cancer cell therapy from Arcellx and Gilead has shown promising results, reducing or eliminating signs of multiple myeloma in 95% of advanced-stage patients. Unlike the leading therapy Carvykti, none of the trial participants experienced movement disorders, making this treatment potentially safer. However, while analysts see anitocabtagene autoleucel as effective, some believe Carvykti may still be preferred due to its established efficacy.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.